Format

Send to

Choose Destination
See comment in PubMed Commons below
Clin Liver Dis. 2003 May;7(2):369-79, vi.

Hepatotoxicity of the thiazolidinediones.

Author information

1
Division of Gastroenterology, Department of Internal Medicine, University of Utah School of Medicine, 30 N 1900 E RM 4R118 SOM Salt Lake City, UT 84132, USA. keith.tolman@hsc.utah.edu

Abstract

Troglitazone, the first of the thiazolidinediones, caused severe hepatotoxicity including liver failure in several patients. It appears, however, that the thiazolidinediones as a class are not as hepatotoxic as troglitazone. Comparative data at comparable dates of usage indicate that pioglitazone and rosiglitazone are not significant hepatotoxins. This is further supported by experimental data that demonstrate that troglitazone, alone among the thiazolidinediones, is toxic in hepatocyte cell culture. All of the thiazolidinediones cause ALT elevations; however, ALT monitoring for hepatotoxicity does not appear to prevent serious liver disease nor reduce patient risk.

PMID:
12879989
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Support Center